Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47

Abstract

Background: Only a few bladder cancer patients benefit from anti-programmed cell death protein 1/programmed cell death ligand 1 immunotherapy. The cluster of differentiation 47 (CD47) plays an important role in tumor immune evasion. CD47 is a highly glycosylated protein, however, the mechanisms governing CD47 glycosylation and its potential role in immunosuppression are unclear. Therefore, this study aimed to evaluate the function of CD47 glycosylation in bladder cancer.

Methods: Western blotting, immunohistochemistry, and flow cytometry were used to measure protein expression, protein-protein interactions, and phagocytosis in bladder cancer. A murine model was employed to investigate the impact of mannosidase alpha class 1B member 1 (MAN1B1) modification of CD47 on anti-phagocytosis in vivo. An ex vivo model, patient-derived tumor-like cell clusters, was used to examine the effect of targeting MAN1B1 on phagocytosis.

Results: Our research identified that aberrant CD47 glycosylation was responsible for its immunosuppression. The glycosyltransferase MAN1B1 responsible for CD47 glycosylation was highly expressed in bladder cancer. Abnormal activation of extracellular signal-regulated kinase (ERK) was significantly associated with MAN1B1 stability by regulating the interaction between MAN1B1 and the E3 ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1). Mechanistically, abnormally activated ERK stabilized MAN1B1, resulting in the glycosylation of CD47 and facilitating immune evasion by enhancing its interaction with signal-regulatory protein alpha (SIRP-α). In vitro and in vivo experiments demonstrated that MAN1B1 knockout weakened CD47-mediated anti-phagocytosis. MAN1B1 inhibitors promoted phagocytosis without causing anemia, offering a safe alternative to anti-CD47 therapy.

Conclusions: This comprehensive analysis uncovered that ERK activation stabilizes MAN1B1 by regulating the interaction between MAN1B1 and HRD1, facilitates immune evasion via CD47 glycosylation, and presents new potential targets and strategies for cancer immunotherapy that do not cause anemia.

Keywords

Bladder cancer / cluster of differentiation 47 / mannosidase alpha class 1B member 1 / immunotherapy / macrophage / phagocytosis / extracellular signal-regulated kinase / HMG-CoA reductase degradation 1

References

[1] Dubrot J, Du PP, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, et al. in vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022; 23(10): 1495-506.

[2] Liu X, Liu L, Ren Z, Yang K, Xu H, Luan Y, et al. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. Cell Rep. 2018; 24(8): 2101-11.

[3] Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPalpha Immune Checkpoint. Immunity. 2020; 52(5): 742-52.

[4] Campbell IG, Freemont PS, Foulkes W, Trowsdale J. An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. Cancer Res. 1992; 52(19): 5416-20.

[5] Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000; 288(5473): 2051-4.

[6] Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014; 32: 25-50.

[7] Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD,, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138(2): 286-99.

[8] von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020; 11(1): 1508.

[9] Betancur PA, Abraham BJ, Yiu YY, Willingham SB, Khameneh F, Zarnegar M, et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nat Commun. 2017; 8: 14802.

[10] Zhang A, Ren Z, Tseng KF, Liu X, Li H, Lu C, et al. Dual targeting of CTLA-4 and CD47 on T(reg) cells promotes immunity against solid tumors. Sci Transl Med. 2021; 13(605): eabg8693.

[11] Zhang X, Wang Y, Fan J, Chen W, Luan J, Mei X, et al. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer. J Immunother Cancer. 2019; 7(1): 346.

[12] Jiang Z, Sun H, Yu J, Tian W, Song Y. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021; 14(1): 180.

[13] Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. N Engl J Med. 2018; 379(18): 1711-21.

[14] Safety Concerns Prompt Pause of Magrolimab Trials. Cancer Discov. 2022; 12(4): 877-8.

[15] Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016; 352(6282): 227-31.

[16] Zhang H, Lu H, Xiang L, Bullen JW, Zhang C, Samanta D, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci U S A. 2015; 112(45): E6215-23.

[17] Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016; 536(7614): 86-90.

[18] Hu H, Cheng R, Wang Y, Wang X, Wu J, Kong Y, et al. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. J Clin Invest. 2023; 133(2): e153470.

[19] Logtenberg MEW, Jansen JHM, Raaben M, Toebes M, Franke K, Brandsma AM, et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPalpha axis and a target for cancer immunotherapy. Nat Med. 2019; 25(4): 612-9.

[20] Lau APY, Khavkine Binstock SS, Thu KL. CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer. Cancers (Basel). 2023; 15(21): 5229.

[21] Myint ZW, Chahine Z, Jayswal R, Bachert E, McDonald RJ, Strup SE, et al. Association of CD47 Expression with Clinicopathologic Characteristics and Survival Outcomes in Muscle Invasive Bladder Cancer. J Pers Med. 2023; 13(6): 885.

[22] Huang Y, Zhang HL, Li ZL, Du T, Chen YH, Wang Y, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021; 12(1): 2672.

[23] Liu Y, Chen S, Wan X, Wang R, Luo H, Chang C, et al. Tryptophan 2,3-dioxygenase-positive matrix fibroblasts fuel breast cancer lung metastasis via kynurenine-mediated ferroptosis resistance of metastatic cells and T cell dysfunction. Cancer Commun (Lond). 2024; 44(11): 1261-86.

[24] Zhang C, Deng Z, Wu J, Ding C, Li Z, Xu Z, et al. HO-1 impairs the efficacy of radiotherapy by redistributing cGAS and STING in tumors. J Clin Invest. 2024; 134(23): e181044.

[25] Vonderheide RH. CD47 blockade as another immune checkpoint therapy for cancer. Nat Med. 2015; 21(10): 1122-3.

[26] Yang Y, Xing R, Liu S, Qin Y, Li K, Yu H, et al. Hydroxypropyltrimethyl ammonium chloride chitosan activates RAW 264.7 macrophages through the MAPK and JAK-STAT signaling pathways. Carbohydr Polym. 2019; 205: 401-9.

[27] Mawby WJ, Holmes CH, Anstee DJ, Spring FA, Tanner MJ. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J. 1994; 304 (Pt 2): 525-30.

[28] Sun L, Li CW, Chung EM, Yang R, Kim YS, Park AH, et al. Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Res. 2020; 80(11): 2298-310.

[29] Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, et al. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018; 33(2): 187-201 e10.

[30] Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019; 15(6): 346-66.

[31] Chung CY, Majewska NI, Wang Q, Paul JT, Betenbaugh MJ. SnapShot: N-Glycosylation Processing Pathways across Kingdoms. Cell. 2017; 171(1): 258-e1.

[32] Scott DW, Chen J, Chacko BK, Traylor JG,, Orr AW, Patel RP. Role of endothelial N-glycan mannose residues in monocyte recruitment during atherogenesis. Arterioscler Thromb Vasc Biol. 2012; 32(8): e51-9.

[33] Alvarez MRS, Grijaldo SJB, Nacario RC, Rabajante JF, Heralde FM, Lebrilla CB, et al. In silico screening-based discovery of inhibitors against glycosylation proteins dysregulated in cancer. J Biomol Struct Dyn. 2023; 41(5): 1540-52.

[34] Jiang XL, Deng B, Deng SH, Cai M, Ding WJ, Tan ZB, et al. Dihydrotanshinone I inhibits the growth of hepatoma cells by direct inhibition of Src. Phytomedicine. 2022; 95: 153705.

[35] Yin S, Xi R, Wu A, Wang S, Li Y, Wang C, et al. Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Sci Transl Med. 2020; 12(549): eaaz1723.

[36] Foot N, Henshall T, Kumar S. Ubiquitination and the Regulation of Membrane Proteins. Physiol Rev. 2017; 97(1): 253-81.

[37] Chen Y, Shao X, Cao J, Zhu H, Yang B, He Q, et al. Phosphorylation regulates cullin-based ubiquitination in tumorigenesis. Acta Pharm Sin B. 2021; 11(2): 309-21.

[38] Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, et al. A new tumor suppressor role for the Notch pathway in bladder cancer. Nat Med. 2014; 20(10): 1199-205.

[39] Xiao X, Shi J, He C, Bu X, Sun Y, Gao M, et al. ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. Nat Commun. 2023; 14(1): 2859.

[40] Li Y, Xie P, Lu L, Wang J, Diao L, Liu Z, et al. An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nat Commun. 2017; 8(1): 347.

[41] Wang HH, Lin LL, Li ZJ, Wei X, Askander O, Cappuccio G, et al. Hypomorphic variants of SEL1L-HRD1 ER-associated degradation are associated with neurodevelopmental disorders. J Clin Invest. 2024; 134(2): e170054.

[42] Morrissey MA, Kern N, Vale RD. CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis. Immunity. 2020; 53(2): 290-302 e6.

[43] Wang HF, Wu JH, Gai JW, Yang SQ, Ma QT, Ma HS, et al. MAN1B1 is associated with poor prognosis and modulates proliferation and apoptosis in bladder cancer. Gene. 2018; 679: 314-9.

[44] Wang X, Chen B, Cao Y, He Y, Chen W. Identification of MAN1B1 as a Novel Marker for Bladder Cancer and Its Relationship with Immune Cell Infiltration. J Oncol. 2022; 2022: 3387671.

[45] Wan J, Guo C, Fang H, Xu Z, Hu Y, Luo Y. Autophagy-Related Long Non-coding RNA Is a Prognostic Indicator for Bladder Cancer. Front Oncol. 2021; 11: 647236.

[46] Rathod M, Chatterjee S, Dutta S, Kalraiya R, Bhattacharyya D, De A. Mannose glycosylation is an integral step for NIS localization and function in human breast cancer cells. J Cell Sci. 2019; 132(20): jcs232058.

[47] Li QK, Lih TM, Wang Y, Hu Y, Hoti N, Chan DW, et al. Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels. Am J Cancer Res. 2022; 12(3): 1323-36.

[48] Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, et al. Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clin Cancer Res. 2021; 27(8): 2190-9.

[49] Jiang YK, Li W, Qiu YY, Yue M. Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer. World J Gastrointest Oncol. 2024; 16(6): 2318-34.

[50] Jiao P, Geng Q, Jin P, Su G, Teng H, Dong J, et al. Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy. Curr Pharm Des. 2018; 24(41): 4911-20.

[51] Zheng M, Li C, Zhou M, Jia R, She F, Wei L, et al. Peptidomimetic-based antibody surrogate for HER2. Acta Pharm Sin B. 2021; 11(9): 2645-54.

[52] Scodeller P, Asciutto EK. Targeting Tumors Using Peptides. Molecules. 2020; 25(4): 808.

[53] Du L, Su Z, Wang S, Meng Y, Xiao F, Xu D, et al. EGFR-Induced and c-Src-Mediated CD47 Phosphorylation Inhibits TRIM21-Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion. Adv Sci (Weinh). 2023; 10(27): e2206380.

[54] Zhang C, Xu M, He S, Huang J, Xu C, Pu K. Checkpoint Nano-PROTACs for Activatable Cancer Photo-Immunotherapy. Adv Mater. 2023; 35(6): e2208553.

[55] Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science. 2023; 381(6662): eabn4180.

[56] Zhu D, Xu R, Huang X, Tang Z, Tian Y, Zhang J, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 2021; 28(6): 1773-89.

[57] Ren W, Xu Z, Chang Y, Ju F, Wu H, Liang Z, et al. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1. Nat Commun. 2024; 15(1): 9.

RIGHTS & PERMISSIONS

2025 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.